CDKN2A and melanoma: Additionally, this cell line expresses BRAFV600E, which activates the MAPK pathway, and expresses AKT1E17K in the context of Cdkn2a and Pten loss, resulting in activation of the PI3K/AKT signaling pathway, which is a common occurrence in human melanoma.